Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Solomon

Showing results (141-150 of 184) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.
Cancer Medicine|March 21, 2022
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancerBenjamin Solomon, Ana Callejo, Jair Bar, et al.
The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
International Journal of Radiation Oncology, Biology, Physics|April 6, 2023
Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung CancerTrudy C Wu, Annalise Stube, Carol Felix, et al.
Targeted Oncology|October 24, 2023
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlbiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2025
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLCSabine Schmid, Georgia Dimopoulou, Paul van Schil, et al.
Clinical and Translational Radiation Oncology|March 11, 2026
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapyAndrea R Filippi, Jair Bar, Daniel C Christoph, et al.
Nature Reviews. Clinical Oncology|March 24, 2021
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Nature Reviews. Clinical Oncology|March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Pageof 19

Showing results (141-150 of 184) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.
Cancer Medicine|March 21, 2022
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancerBenjamin Solomon, Ana Callejo, Jair Bar, et al.
The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
International Journal of Radiation Oncology, Biology, Physics|April 6, 2023
Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung CancerTrudy C Wu, Annalise Stube, Carol Felix, et al.
Targeted Oncology|October 24, 2023
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaAlbiruni R Abdul Razak, Hung-Ming Wang, Jang-Yang Chang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2025
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLCSabine Schmid, Georgia Dimopoulou, Paul van Schil, et al.
Clinical and Translational Radiation Oncology|March 11, 2026
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapyAndrea R Filippi, Jair Bar, Daniel C Christoph, et al.
Nature Reviews. Clinical Oncology|March 24, 2021
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Nature Reviews. Clinical Oncology|March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Pageof 19